Estradiol and drospirenone tablets can improve the bone mineral density and bone turnover markers:a prospective, self-controlled study
HU Lun
WANG Aiming
SONG Zhiqin
ZHAO Yong
LI Min
SUN Ying
YAN Ling
LI Xiuqin
Abstract：Objective To investigate the effects of estradiol and drospirenone tablets ( E2/DRSP) on bone mineral density and bone turnover markers.Methods This was a prospective, self-controlled cohort study.Postmenopausal women who were treated with E2/DRSP for at least 6 months from March 2012 to June 2013 and at the age of 45—60 (52.5±3.4) years were enrolled. Comparisons were made by bone mineral density and bone turnover markers ( bone alkaline phospha-tase and tartrate-resistant acid phosphatase) between pre-and post-treatment.Results A total of 64 women were enrolled.Symptoms of menopausal syndrome alleviated significantly.Bone mineral den-sities of the lumber spine [(1.016 7±0.104 6) g/cm2 vs (1.025 0±0.019 1) g/cm2] and the hip [(0.455 5±0.089 9) g/cm2 vs (0.484 7±0.138 0) g/cm2] were significantly improved after 6 months of treatment ( P<0.05 ) .Levels of bone alkaline phosphatase [ ( 65.82 ±14.75 ) U/L at baseline vs (61.14±12.38) U/L, (58.77±11.35) U/L at 3rd and 6th month, respectively, P<0.05] and tartrate-resistant acid phosphatase [(6.15±3.02) U/L at baseline vs (5.99±2.98) U/L, (4.90±2.90) U/L at 3rd and 6th month, respectively, P<0.05)] were significantly decreased after treatment of E2/DRSP .Conclusion E2/DRSP can alleviate symptoms of menopausal syn-drome effectively, and also has benefits for bone mineral density and bone metabolism.
Keywords：Estradiol and drospirenone tablets ( E2/DRSP )Hormone replacement therapyBone mineral densityBone metabolism
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 290-292 )